Project/Area Number |
21790290
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Single-year Grants |
Research Field |
General medical chemistry
|
Research Institution | Saitama Medical University |
Principal Investigator |
HISHIDA Tomoaki Saitama Medical University, 医学部, 研究員 (80521062)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
Keywords | 移植・再生医療 / 癌 / 再生医学 |
Research Abstract |
ES and iPS cells have not only pluripotency but also tumorigenic activity, and we therefore must overcome their oncogenic property. We focused on LATS2, a tumor suppressor gene and examined the role and involvement of LATS2 in tumorigenic activity of ES cells. We found that forced LATS2 expression reduced the cell growth and oncogenic property of ES cells. However, several studies indicated that LATS2 protein expression gradually declined as ES cells grew, suggesting that there might exist the protein degradation system for the factors having anti-oncogenic activity in ES cells.
|